Sources: Twitter's board is considering a poison pill after Elon Musk's bid; a source says another plan under consideration is saying that the offer is too low
Twitter Inc.'s board is considering adopting a measure that would protect the company from hostile acquisition bids …
Context & Ripple Effects
The board had already signaled that it regarded Musk’s approach as unwelcome; weighing a shareholder-rights plan that dilutes large stakes turns that stance into a concrete negotiating defense. The parallel argument that the offer undervalues Twitter gives directors a shareholder-value rationale for resisting it.
The defensive posture did not end consideration of a sale. Musk’s later financing disclosure led the board to take the proposal more seriously, while Apollo Global and Morgan Stanley explored possible involvement, widening the set of paths the board could assess.
First-order effects
- Musk’s bid moves into a board-controlled process: a poison pill would make it harder to build a controlling position without director approval, while a low-price finding supports rejection.
- Twitter shareholders gain time and bargaining leverage because the board can compare Musk’s proposal with alternatives rather than respond to a rapid accumulation of shares.
Second-order effects
- Musk’s disclosed financing becomes central to overcoming the board’s resistance, as the later more serious board review after his financing filing shows.
- Potential financial partners and rival bidders gain an opening to participate, since a defended company can use outside interest to test whether Musk’s price is its best available option.
Third-order effects
- The episode illustrates how takeover defenses shift leverage from a hostile bidder’s public offer toward directors’ evaluation of price, financing certainty, and competing proposals.
- If this pattern persists, high-profile platform acquisitions will be decided less by a bidder’s initial premium than by whether boards can sustain a formal process that produces a superior or more certain alternative.
The trend: Hostile bids for major platforms are increasingly becoming financing-and-process contests in which boards use defensive tools to control the timetable and price discovery.